Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

Tuspetinib is a convenient once daily oral agent, and the TUS+VEN+AZA triplet has the potential to treat the larger AML population in a mutation agnostic manner, not just narrow subpopulations.

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML ... On the other hand, NPM1 mutation also was noted as a favorable prognostic factor.

evaluated the safety and efficacy of its experimental drug revumenib in adults with relapsed or refractory mutant NPM1 AML, a difficult-to-treat form of AML with specific genetic mutations.

“More than half of AML patients with an NPM1 mutation will relapse with poor survival outcomes ii, making it a significant area of unmet medical need in the frontline setting,” said Takeyoshi ...